🇺🇸·2h agoIndustry
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Publisher
M
Merck & Co. (MSD) News
USA
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Merck & Co. (MSD) News
- Region
- USA
- Scope
- Industry
- Published
- September 24, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck & Co. (MSD) News
Scope: Industry
Related coverage
More related coverage
Interpharma Switzerland/6h ago
Klinische Forschung unter Druck: Die Schweiz verliert den Anschluss
Chugai Pharmaceutical News/6h ago
ロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAGINATION試験の中間解析結果）
Chugai Pharmaceutical/6h ago
Roche’s Announcement Regarding Sefaxersen (Announcement of Interim Analysis Results from the Phase III IMAGINATION Study)
Otsuka Pharmaceutical/12h ago